Literature DB >> 14724582

Rad51 overexpression promotes alternative double-strand break repair pathways and genome instability.

Christine Richardson1, Jeremy M Stark, Melissa Ommundsen, Maria Jasin.   

Abstract

Genomic instability is characteristic of tumor cells, and a strong correlation exists between abnormal karyotype and tumorigenicity. Increased expression of the homologous recombination and DNA repair protein Rad51 has been reported in immortalized and tumor cells, which could alter recombination pathways to contribute to the chromosomal rearrangements found in these cells. We used a genetic system to examine the potential for multiple double-strand breaks to lead to genome rearrangements in the presence of increased Rad51 expression. Analysis of repair revealed a novel class of products consistent with crossing over, involving gene conversion associated with an exchange of flanking markers leading to chromosomal translocations. Increased Rad51 also promoted aneuploidy and multiple chromosomal rearrangements. These data provide a link between elevated Rad51 protein levels, genome instability, and tumor progression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14724582     DOI: 10.1038/sj.onc.1207098

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  99 in total

1.  Rsf-1, a chromatin remodeling protein, induces DNA damage and promotes genomic instability.

Authors:  Jim Jinn-Chyuan Sheu; Bin Guan; Jung-Hye Choi; Athena Lin; Chia-Huei Lee; Yi-Ting Hsiao; Tian-Li Wang; Fuu-Jen Tsai; Ie-Ming Shih
Journal:  J Biol Chem       Date:  2010-10-05       Impact factor: 5.157

2.  High levels of RAD51 perturb DNA replication elongation and cause unscheduled origin firing due to impaired CHK1 activation.

Authors:  Ann Christin Parplys; Jasna Irena Seelbach; Saskia Becker; Matthias Behr; Agnieszka Wrona; Camilla Jend; Wael Yassin Mansour; Simon Andreas Joosse; Horst-Werner Stuerzbecher; Helmut Pospiech; Cordula Petersen; Ekkehard Dikomey; Kerstin Borgmann
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

3.  RAD51 Gene 135G/C polymorphism and ovarian cancer risk: a meta-analysis.

Authors:  Xingzhong Hu; Suyu Sun
Journal:  Int J Clin Exp Med       Date:  2015-12-15

Review 4.  Tools To Live By: Bacterial DNA Structures Illuminate Cancer.

Authors:  Jun Xia; Qian Mei; Susan M Rosenberg
Journal:  Trends Genet       Date:  2019-04-05       Impact factor: 11.639

5.  Synthesis, molecular modeling, and biological evaluation of novel RAD51 inhibitors.

Authors:  Jiewen Zhu; Hongyuan Chen; Xuning Emily Guo; Xiao-Long Qiu; Chun-Mei Hu; A Richard Chamberlin; Wen-Hwa Lee
Journal:  Eur J Med Chem       Date:  2015-04-09       Impact factor: 6.514

6.  Brh2-Dss1 interplay enables properly controlled recombination in Ustilago maydis.

Authors:  Milorad Kojic; Qingwen Zhou; Michael Lisby; William K Holloman
Journal:  Mol Cell Biol       Date:  2005-04       Impact factor: 4.272

7.  Genetic steps of mammalian homologous repair with distinct mutagenic consequences.

Authors:  Jeremy M Stark; Andrew J Pierce; Jin Oh; Albert Pastink; Maria Jasin
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

Review 8.  Clinically Applicable Inhibitors Impacting Genome Stability.

Authors:  Anu Prakash; Juan F Garcia-Moreno; James A L Brown; Emer Bourke
Journal:  Molecules       Date:  2018-05-13       Impact factor: 4.411

9.  Human Rad52-mediated homology search and annealing occurs by continuous interactions between overlapping nucleoprotein complexes.

Authors:  Eli Rothenberg; Jill M Grimme; Maria Spies; Taekjip Ha
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-11       Impact factor: 11.205

10.  Overexpression of RAD51 occurs in aggressive prostatic cancer.

Authors:  Anita Mitra; Charles Jameson; Yolanda Barbachano; Lydia Sanchez; Zsofia Kote-Jarai; Susan Peock; Nayanta Sodha; Elizabeth Bancroft; Anne Fletcher; Colin Cooper; Douglas Easton; Rosalind Eeles; Christopher S Foster
Journal:  Histopathology       Date:  2009-12       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.